An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen-Reference-Cited by-同舟云学术

An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen

Published:2022-12 Issue: Volume:72 Page:11-21
ISSN:1871-6784
Container-title:New Biotechnology
language:en
Short-container-title:New Biotechnology

Author:

Limonta-Fernández Miladys,Chinea-Santiago Glay,Martín-Dunn Alejandro Miguel,Gonzalez-Roche Diamile,Bequet-Romero Monica,Marquez-Perera Gabriel,González-Moya Isabel,Canaan-Haden-Ayala Camila,Cabrales-Rico Ania,Espinosa-Rodríguez Luis Ariel,Ramos-Gómez Yassel,Andujar-Martínez Ivan,González-López Luis Javier,de la Iglesia Mariela Perez,Zamora-Sanchez Jesus,Cruz-Sui Otto,Lemos-Pérez Gilda,Cabrera-Herrera Gleysin,Valdes-Hernández Jorge,Martinez-Diaz Eduardo,Pimentel-Vazquez Eulogio,Ayala-Avila Marta,Guillén-Nieto Gerardo

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Bioengineering,Biotechnology

Reference42 articles.

1. Mammalian expression system and improvisation for high production;Kodati;Int J Sci Res,2016

2. Viral contamination in biologic manufacture and implications for emerging therapies;Barone;Nat Biotechnol,2020

3. Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells;Arbeitman;Sci Rep,2020

4. Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins;Karbalaei;J Cell Physiol,2020

5. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients;Premkumar;Sci Immunol,2020

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diverse approaches to express recombinant spike protein: A comprehensive review;Protein Expression and Purification;2024-11

2. Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial;Vaccines;2024-09-01

3. Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE);Vaccine;2024-09

4. Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris;PLOS Pathogens;2024-08-30

5. Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges;ACS Nano;2024-08-26